{"id":"NCT00685373","sponsor":"Novartis","briefTitle":"Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","officialTitle":"An Open-label, Long-term Safety and Efficacy Study of ACZ885 (Anti-interleukin-1β Monoclonal Antibody) Administered for at Least 6 Months in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-04","completion":"2010-04","firstPosted":"2008-05-28","resultsPosted":"2011-05-27","lastUpdate":"2016-11-04"},"enrollment":166,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cryopyrin-Associated Periodic Syndromes","Familial Cold Autoinflammatory Syndrome","Muckle Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease"],"interventions":[{"type":"DRUG","name":"Canakinumab (ACZ885)","otherNames":[]}],"arms":[{"label":"Canakinumab (ACZ885)","type":"EXPERIMENTAL"}],"summary":"This will provided long-term safety and efficacy data for ACZ885 (a fully human anti-interleukin-1β \\[anti-IL-1β\\] monoclonal antibody) given as an injection subcutaneously in patients who participated in the CACZ885A2102 (NCT00487708), CACZ885D2201 (NCT00685373) or CACZ885D2304(NCT00465985) studies or newly identified patients with the following cryopyrin-associated periodic syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome or Neonatal Onset Multisystem Inflammatory Disease.\n\nThe duration of this study was 6 months with a maximum duration of 2 years","primaryOutcome":{"measure":"The Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs), Discontinuation of Study Drug Due to an AE, Infections and Infestations and Injection Site Reactions","timeFrame":"2 years depending on when the participant enters the study","effectByArm":[{"arm":"Canakinumab (ACZ885)","deltaMin":150,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":28,"countries":["United States","Belgium","France","Germany","India","Italy","Spain","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["21859692"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":166},"commonTop":["Nasopharyngitis","Headache","Rhinitis","Arthralgia","Diarrhoea"]}}